Toxicity

Toxicity is the intrinsic degree to which a substance, such as a drug or chemical, can cause adverse effects on a living organism. It is a fundamental concept in toxicology and a critical component of risk management in product development. Toxicity assessment follows international standards like the OECD Guidelines for the Testing of Chemicals and the ISO 10993 series for medical devices. In risk assessment, toxicity represents the 'hazard identification' step. It is distinct from 'risk,' which is the probability of harm occurring upon exposure to the toxic substance. A substance's toxicity is an inherent property, whereas risk depends on the level and duration of exposure.

In enterprise risk management, toxicity assessment is a structured, four-step process to ensure product safety. 1) **Hazard Identification**: Screen potential toxic properties using in silico, in vitro, and literature data. 2) **Dose-Response Assessment**: Establish the relationship between dose and adverse effects through preclinical studies, compliant with OECD or ISO standards, to determine the No-Observed-Adverse-Effect Level (NOAEL). 3) **Exposure Assessment**: Evaluate potential human exposure under intended use conditions. 4) **Risk Characterization**: Integrate all data to determine the margin of safety and decide if the risk is acceptable. For example, a global pharma company using organ-on-a-chip technology for early liver toxicity screening reduced its candidate failure rate by 25% and identified issues months earlier than with traditional methods.

Taiwanese enterprises face three key challenges in adopting advanced toxicity assessment: 1) **Regulatory Lag**: The local regulatory acceptance of New Approach Methodologies (NAMs), such as organoids or AI/ML models, can lag behind the US FDA and EMA, impacting global market access. 2) **Talent Shortage**: There is a scarcity of interdisciplinary experts with skills in both toxicology and data science needed to interpret complex high-throughput screening data. 3) **High Costs**: Establishing in-house GLP-compliant labs or outsourcing to CROs is expensive, posing a significant financial barrier for startups and SMEs. Solutions include proactive regulatory engagement with the TFDA, forming university-industry partnerships for talent development, and leveraging government grants or industry consortia to share costs.

Winners Consulting specializes in toxicity for Taiwan enterprises, delivering compliant management systems within 90 days. Free consultation: https://winners.com.tw/contact